Evaluation of Barriers to Completion of Breast Cancer Treatment at a Tertiary Teaching and Referral Center in Kenya
Evaluation of Barriers to Completion of Breast Cancer Treatment at a Tertiary Teaching and Referral Center in Kenya
批准号:
10623722
负责人:
BEN H PARK
金额:
$12.59万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-07 至 2024-07-31
关键词:
Academic Medical CentersAddressAdvocateAntigen PresentationAntigen TargetingAreaAtlasesAwardBRCA deficientBasic ScienceBioinformaticsBiometryBreastBreast Cancer PatientBreast Cancer Risk FactorBreast Cancer TreatmentCDK4 geneCancer CenterCarboplatinCellsClinicalClinical InvestigatorClinical ResearchClinical TrialsCollaborationsDNA DamageDatabasesDevelopmentDiagnosisDiseaseDrug CombinationsERBB2 geneEducational process of instructingEnsureEstrogen AntagonistsEstrogen ReceptorsEstrogensEvaluationFibroblast Growth Factor ReceptorsFulvestrantFundingFutureGenomicsGoalsHealthHumanHuman ResourcesImmuneImmune EvasionImmune responseImmunoPETImmunophenotypingImmunotherapeutic agentImmunotherapyIn VitroIndividualInformaticsInternationalInvestigationKenyaMEK inhibitionMEKsMediatingMetastatic breast cancerModelingMolecular TargetMutateMyelogenousNeoplasmsPDL1 inhibitorsPaclitaxelPathologyPatient SelectionPatient-Focused OutcomesPatientsPharmaceutical PreparationsPoly(ADP-ribose) PolymerasesPositron-Emission TomographyPrognosisRefractoryResearch PersonnelResearch Project GrantsResistanceResource SharingResourcesSolid NeoplasmTestingTherapeuticTherapeutic Clinical TrialTherapeutic InterventionTissuesTranslational ResearchTumor ImmunityUp-RegulationValidationWomanWorkanti-PD-L1 therapyanticancer researchbasebiomarker identificationbiomedical referral centercancer immunotherapycancer subtypescareercheckpoint therapychemotherapyclinical investigationdrug discoveryexperiencehormone therapyimmunoregulationimprovedimproved outcomeinhibitorinhibitor therapyinnovationinnovative technologiesinsightmalignant breast neoplasmmammarymeetingsmembermenmolecular targeted therapiesmouse modelmultidisciplinarynew therapeutic targetprogramsrecruitresistance mechanismresponseresponse biomarkertranslational goaltriple-negative invasive breast carcinomatumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT: OVERALL
This is the third competing renewal application of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Breast
Cancer. Using the well-established framework of a very active and strong multidisciplinary VICC Breast Cancer
Program that is robustly supported by the SPORE mechanism, we have made significant progress in our current
project period. Our highly successful Developmental Research Projects (DRP) and Career Enhancement
Programs (CEP) continue to catalyze new ideas and new investigators in translational breast cancer research,
including two projects in this continuing renewal. We are uniquely poised to complete the proposed work and to
be even more productive in the years to come, thanks to an exceptional multidisciplinary program and
established productive collaborations with other Breast Cancer Programs and SPOREs, as well as national and
international collaborations. Our overall goal remains the same: To conduct collaborative, multidisciplinary and
mechanism-based translational research that will have the highest possible impact for women and men with or
at risk for breast cancer. After significant planning and internal and external advisory board evaluation, we
propose four bi-directional translational projects addressing basic, translational and clinical research questions
of importance in human breast cancer; Projects 1 and 2 are continuation projects, Projects 3 and 4 are new
projects that have evolved from two CEP awards in the current funding cycle: Project 1 - Mechanisms of
Resistance to Endocrine Therapy in ER+ Breast Cancer; Project 2 - Strategies to Improve Outcomes for TNBC
Patients Integrating Subtype-specific Genomic and Immune-based Discoveries; Project 3 - Targeting the DNA
Damage Response in Breast Cancer; Project 4 - Targeting Antigen Presentation to Improve Immunotherapy
Responses in Breast Cancer. The application also includes DRP and CEP, and four highly integrated shared
core resources: Administration and Engagement, Biostatistics and Bioinformatics, Pathology and Tissue
Informatics, and Immunophenotyping. The cores bring innovative technology and resources, including additional
personnel with project-specific expertise, to the overall VICC Breast SPORE Program and do not duplicate pre-
existing shared resources available at VICC or Vanderbilt University Medical Center (VUMC). With a focus on
human endpoints, six interventional therapeutic clinical trials are associated with the highly translational projects
in this proposal, all based on extensive collaboration between world-class basic and clinical investigators. We
have firmly established a true multidisciplinary team that successfully implements innovative clinical trials to test
hypotheses that result from in vitro and patient studies, and that will continue to have productive translational
collaborations with other Breast Cancer Programs and SPOREs as well as national and international groups.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer
-
批准号:10380582
-
项目类别:
-
资助金额:$22.87万
-
财政年份:2018
-
负责人:BEN H PARK
-
依托单位:
Molecular complete response in blood as a predictor for pathologic complete response after neoadjuvant therapy for breast cancer
-
批准号:9520587
-
项目类别:
-
资助金额:$22.47万
-
财政年份:2018
-
负责人:BEN H PARK
-
依托单位:
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer
-
批准号:10592440
-
项目类别:
-
资助金额:$14.5万
-
财政年份:2018
-
负责人:BEN H PARK
-
依托单位:
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer
-
批准号:9925755
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2018
-
负责人:BEN H PARK
-
依托单位:
Circulating plasma tumor DNA as a biomarker for early stage breast cancer
-
批准号:9392301
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2016
-
负责人:BEN H PARK
-
依托单位:
Core 3: Translational Pathology Shared Resource Core
-
批准号:10328042
-
项目类别:
-
资助金额:$2.79万
-
财政年份:2011
-
负责人:BEN H PARK
-
依托单位:
Core 3: Translational Pathology Shared Resource Core
-
批准号:10693374
-
项目类别:
-
资助金额:$2.73万
-
财政年份:2011
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest.
-
批准号:7036929
-
项目类别:
-
资助金额:$29.49万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest.
-
批准号:7753761
-
项目类别:
-
资助金额:$6.12万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest.
-
批准号:7537893
-
项目类别:
-
资助金额:$5.96万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest.
-
批准号:7362430
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest.
-
批准号:7745470
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest.
-
批准号:7352000
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest
-
批准号:7174193
-
项目类别:
-
资助金额:$21.51万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest.
-
批准号:7535591
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2006
-
负责人:BEN H PARK
-
依托单位:
Genetic effectors of TGF-beta induced growth and arrest
-
批准号:7032632
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2005
-
负责人:BEN H PARK
-
依托单位:
SPORE in Breast Cancer
-
批准号:10456735
-
项目类别:
-
资助金额:$203.14万
-
财政年份:2003
-
负责人:BEN H PARK
-
依托单位:
SPORE in Breast Cancer
-
批准号:10704039
-
项目类别:
-
资助金额:$218.15万
-
财政年份:2003
-
负责人:BEN H PARK
-
依托单位:
SPORE in Breast Cancer
-
批准号:10226879
-
项目类别:
-
资助金额:$215.34万
-
财政年份:2003
-
负责人:BEN H PARK
-
依托单位:
Clinical and Pathologic Response to Neoadjuvant Chemotherapy for Breast Cancer
-
批准号:10845365
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2003
-
负责人:BEN H PARK
-
依托单位:
海外基金